ExonHit to Buy RedPath Integrated Pathology | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics said today that it has agreed to buy personalized diagnostics company RedPath Integrated Pathology in a deal that could be worth a total of $32 million.

Paris-based ExonHit plans to buy RedPath, a developer of DNA-based cancer tests, for $12.5 million upfront, another $10 million in stock, and for sales milestone payments that could total another $9.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.